Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is a single infusion of zoledronic acid superior to risedronate for the treatment of Paget's disease?

Nature Clinical Practice Endocrinology & Metabolism volume 2, pages 252–253 (2006)Cite this article

boxed-textReid IR et al. (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 353: 898–908

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kanis JA (1998) Pathophysiology and Treatment of Paget's Disease of Bone, edn 2. London: Martin Dunitz Ltd

    Google Scholar 

  2. Selby PL et al. (2002) Guidelines on the management of Paget's disease of bone. Bone 31: 366–373

    Article  CAS  Google Scholar 

  3. Schweitzer DH et al. (1993) Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 8: 175–182

    Article  CAS  Google Scholar 

  4. Miller PD et al. (1999) A randomized, double-blind comparison of risedronate and etidronate in the management of Paget's disease of bone. Am J Med 106: 513–520

    Article  CAS  Google Scholar 

  5. Siris E et al. (1996) Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81: 961–967

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Marie Lofthouse, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine, Consultant Physician and Director of Bone and Mineral Research at the Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, The Netherlands

    Socrates E Papapoulos

Authors
  1. Socrates E Papapoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Socrates E Papapoulos.

Ethics declarations

Competing interests

SE Papapoulos has received research support and/or honoraria from all major pharmaceutical companies involved in bisphosphonate development. (Merck & Co, Novartis, Roche/GSK, Alliance for Better Bone Health- Procter & Gamble-Aventis-Sanofi)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papapoulos, S. Is a single infusion of zoledronic acid superior to risedronate for the treatment of Paget's disease?. Nat Rev Endocrinol 2, 252–253 (2006). https://doi.org/10.1038/ncpendmet0166

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0166

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing